Skip to main content

What our clients say

“Writing a H2020 proposal is an enormous task and requires not only excellent science but also substantial experience in proposal writing. accelopment also provides useful assistance in terms of project management and communication.“

Dr. Ekaterine Berishvili

VANGUARD Project Coordinator
University of Geneva, Switzerland

New Generation Cell Therapy: Bioartificial Pancreas to Cure Type 1 Diabetes

Forty million individuals worldwide suffer from type 1 diabetes. This disease is managed by insulin therapy in a vast majority of patients because of the limited accessibility of beta cell replacement therapies (pancreas or islet of Langerhans transplantation). There is an urgent need for the development of a beta cell replacement therapy that will be available to larger numbers of type 1 diabetic patients.

The VANGUARD project aims to deliver an Advanced Therapeutic Medicinal Product (ATMP) of high translational potential, with properties of increased functionality and implantability and protection from immune destruction. We will construct a bioartificial pancreas by assembling insulin-producing organoids, composed of islet cells, human amniotic epithelial cells (hAEC) and blood outgrowth endothelial cells (BOECs), into an amniotic membrane-derived hydrogel. Components of the amniotic membrane will provide extracellular matrix and mechanical protection and confer their well-defined anti-inflammatory and immunomodulatory properties to the constructs. hAECs will be genome-edited to overexpress and locally release immunomodulatory molecules (HLA-G, HLA-E, CD47 and PD-L1) and endothelial cells will enhance graft revascularization. Functionality, biocompatibility, potency and safety of the bioartificial pancreas will be assessed in vitro and in vivo by implantation in mice reconstituted with a human immune system as pre-clinical model.

The consortium consists of 6 academic institutions with leading scientists in their field, 2 SMEs and 1 NGO with expertise in ethical and social aspects of transplantation.

The ATMP delivered upon completion of the project will provide a model for rapid development of a bioartificial pancreas, utilizing “infinite” sources of insulin-producing cells (stem cell-derived, xenogeneic), and available to all type 1 diabetic patients before they develop the devastating chronic complications of the disease.

Read more about VANGUARD on Horizon, the official EU magazine for EU-funded projects: https://horizon-magazine.eu/article/lab-grown-and-do-it-yourself-two-emerging-routes-artificial-pancreas.html

This project contributes to the UN Sustainable Development Goal (SDG) 3.

Facts

Programme:

H2020-SC1-2019

Duration:

01.01.2020 – 30.06.2025

Budget:

6.8 million euro

Area:

Health, diabetes, cell therapy

Our Services:

Proposal Writing
Grant Preparation
Management
Dissemination

Coordinator

Université de Genève, CH

Partners

Università degli Studi del Piemonte Orientale Amedeo Avogadro, IT
Université Lyon 1 Claude Bernard, FR
Ospedale San Raffaele SRL, IT
Ludwig-Maximilians-Universität München, DE
Kugelmeiers AG, CH
European Society for Organ Transplantation, NL
Erasmus Universitair Medisch Centrum Rotterdam, NL
accelopment Schweiz AG, CH

Our Team

My passion is to work with highly skilled scientists and innovative thinkers from industry and academia to build solutions for a sustainable future.

Dr. Jeanette Müller

CEO
Horizon EuropeHealthEuropean Innovation Council
©accelopment Schweiz AG
+41 44 455 66 00 
info@accelopment.com  
ISO 9001 certified
© 2026 accelopment. All rights reserved.